Prime Medicine (PRME) closed at $3.84 on November 19, 2026, up 0.5% from the previous close, on volume of 3,816,933 shares (30-day average 5,477,486).
Data as of November 19, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 12, 2026 | Call Spread | 21-Jan-282 : 5 C | 1,704 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Cathie Wood's weekly recap: boosts Nvidia, CoreWeave, Archer Aviation; pares Tempus AI, Palantir
Seeking Alpha News (Mon, 16-Nov 7:05 AM ET)
TipRanks (Mon, 16-Nov 6:40 AM ET)
Prime Medicine closes $143.7 million stock offering with full underwriter option exercised
Market Chameleon (Fri, 13-Nov 10:15 AM ET)
Globe Newswire (Thu, 12-Nov 4:15 PM ET)
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Thu, 12-Nov 4:01 PM ET)
Prime Medicine Announces Pricing of Public Offering of Common Stock
Globe Newswire (Tue, 10-Nov 9:40 PM ET)
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
Prime Medicine to Present at Jefferies Global Healthcare Conference
Globe Newswire (Mon, 9-Nov 8:00 AM ET)
PRME begins first-in-human PM577a study as first Wilson disease patient is dosed
Market Chameleon (Tue, 6-Oct 7:35 AM ET)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Prime Medicine trades on the NASDAQ stock market under the symbol PRME.
As of November 20, 2026, PRME stock price declined to $3.57 with 3,755,812 million shares trading.
PRME has a beta of 1.65, meaning it tends to be more sensitive to market movements. PRME has a correlation of 0.06 to the broad based SPY ETF.
PRME has a market cap of $796.08 million. This is considered a Small Cap stock.
Last quarter Prime Medicine reported $4 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.
In the last 3 years, PRME traded as high as $9.86 and as low as $1.11.
The top ETF exchange traded funds that PRME belongs to (by Net Assets): ARKG, XBI, VTI, IWM, VXF.
PRME has underperformed the market in the last year with a price return of -4.0% while the SPY ETF gained +5.4%. However, in the short term, PRME had mixed performance relative to the market. It has outperformed in the last 3 months, returning +0.8% vs -9.9% return in SPY. But in the last 2 weeks, PRME shares have been beat by the market, returning -19.8% compared to an SPY return of -5.7%.
PRME support price is $3.55 and resistance is $4.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRME shares will trade within this expected range on the day.